ORPHA:99868
Thymic carcinoma
Publications
7,232
Trials
63
Interventional, condition-specific
Researchers
1,335
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
Thymic carcinoma (TC) is a type of thymic epithelial neoplasm characterized by a high malignant potential.
How rare: How common this is has not been clearly measured.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0006451
- UMLS:C0205969
- NCIT:C7569
- NCIT:C7612
Additional Mondo synonyms (11)
carcinoma of thymus · malignant thymoma · thymic carcinoma · thymic carcinoma (excluding well differentiated thymic carcinoma) · thymic carcinoma excluding well differentiated thymic carcinoma · thymoma type C · thymoma, malignant · thymoma, malignant (morphologic abnormality) · thymoma, type C (morphologic abnormality) · thymus carcinoma · type C thymoma
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
7,232 matched papers (4,132 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialPresent
63 matched on ClinicalTrials.gov (17 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
7,232
7,232 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
7,232 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
4,132 in the last 10 years · low confidence
Phrase hits: 7,232 · MeSH hits: 0
Who's working on it?
1,335
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Inoue M7 papers · 2026
Division of Thoracic Surgery, Department of Surgery, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Papers in Europe PMC - 02Fang W6 papers · 2026
Shanghai Chest Hospital, Jiaotong University Medical School, Shanghai, People's Republic of China.
Papers in Europe PMC - 03Ishihara S6 papers · 2026
Division of Thoracic Surgery, Department of Surgery, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Papers in Europe PMC - 04Okada S6 papers · 2026
Division of Thoracic Surgery, Department of Surgery, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Papers in Europe PMC - 05
- 06Furuya T5 papers · 2026
Division of Thoracic Surgery, Department of Surgery, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Papers in Europe PMC - 07
- 08Girard N5 papers · 2025
Department of Medical Oncology, Institut Curie, Paris, France.
Papers in Europe PMC - 09Lucchi M5 papers · 2025
Thoracic Surgery, Department of Surgical, Medical and Molecular Pathology and Critical Care, University of Pisa, Pisa, Italy.
Papers in Europe PMC - 10Marx A5 papers · 2026
Institute of Pathology, University Medical Center Göttingen, Göttingen, Germany.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
63
interventional trials for this specific condition
63 interventional trials matched this specific condition name; 17 currently recruiting in our sample.
Data as of 27 July 2026
63 interventional trials — more than 73% of diseases in the trials denominator have none at all (5114 of 7003; this disease is at the 97.6th percentile).
low confidence · 97.6th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
63 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT06692062·RECRUITING·Hypofractionated Radiotherapy for Thymic Epithelial Tumors
Conditions: Thymoma and Thymic Carcinoma · Thymoma · Thymic Cancer · Thymic Epithelial Tumor·Matched via name phrase
- NCT06838910·RECRUITING·Tislelizumab Combined With Anlotinib as Second-line Therapy in Thymoma and Thymic Carcinoma
Conditions: Thymic Carcinoma · Thymoma·Matched via name phrase
- NCT05104736·RECRUITING·PT-112 in Subjects With Thymoma and Thymic Carcinoma
Conditions: Thymic Epithelial Tumor · Recurrent Thymoma · Thymic Cancer·Matched via name phrase
- NCT04731610·RECRUITING·Randomized, Multicenter, Phase III Trial to Assess Conformal Post-operative Radiotherapy vs. Surveillance After Complete Resection of Stage II/III Thymoma (RADIO-RYTHMIC-01)
Conditions: Thymoma Malignant Recurrent·Matched via name phrase
- NCT07598955·RECRUITING·Target-Selected CAR-NK Cells (CD30, CD5, or Mesothelin) for Relapsed/Refractory B2 Thymoma or Thymic Carcinoma
Conditions: B2 Thymoma · Thymic Carcinoma·Matched via name phrase
- NCT06980077·RECRUITING·Ivonescimab for the Treatment of Thymic Cancer
Conditions: Thymus Carcinoma·Matched via name phrase
- NCT07463313·NOT YET RECRUITING·6 vs 3 Cycles of Neoadjuvant Chemotherapy for Potentially Resectable Locally Advanced Thymic Epithelial Tumors
Conditions: Thymoma and Thymic Carcinoma·Matched via name phrase
- NCT07324629·NOT YET RECRUITING·Sacituzumab Tirumotecan in Participants With Locally Advanced or Metastatic Thymic Carcinoma
Conditions: Thymic Carcinoma·Matched via name phrase
- NCT03295227·RECRUITING·Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer
Conditions: Stage III Thymoma AJCC v8 · Stage IIIA Thymoma AJCC v8 · Stage IIIB Thymoma AJCC v8 · Stage IV Thymoma AJCC v8·Matched via name phrase
- NCT07479628·NOT YET RECRUITING·Neoadjuvant Adebrelimab Plus CRT for Locally Advanced Thymic Carcinoma
Conditions: Thymic Carcinoma·Matched via name phrase
- NCT06402708·RECRUITING·Postoperative Adjuvant Chemotherapy for Thymic Cancer (FUSCC-Thymic 3)
Conditions: Thymic Carcinoma·Matched via name phrase
- NCT06248515·RECRUITING·A Phase II Trial of Sacituzumab Govitecan in Patients With Advanced Thymic Epithelial Tumors
Conditions: Thymoma · Thymic Carcinoma·Matched via name phrase
- NCT07181720·RECRUITING·CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors
Conditions: Renal Cell Carcinoma (RCC) · Lung Cancer · Anaplastic Thyroid Carcinomas · Ovarian Cancer·Matched via name phrase
- NCT06019468·RECRUITING·Neoadjuvant Treatment For Locally Advanced Thymic Cancer
Conditions: Thymic Carcinoma·Matched via name phrase
- NCT06186726·RECRUITING·Clinical Study of Carbon Ion Radiotherapy Combined With Chemotherapy for Thymic Epithelial Tumors
Conditions: Carbon Ion Radiotherapy, Thymoma, Thymic Carcinoma, Radiotherapy, Chemotherapy·Matched via name phrase
Observational and natural-history studies
7 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT06301945·RECRUITING·Artificial Intelligence Prediction Tool in Thymic Epithelial Tumors
Conditions: Thymic Epithelial Tumor · Thymic Carcinoma · Thymoma · Thymoma and Thymic Carcinoma·Matched via name phrase
- NCT07429851·RECRUITING·CompArative Analysis Between, Thymic, pulmonaRy and Pancreatic Well Differentiated High Grade Neuroendocrine Tumors
Conditions: Neuroendocrine Carcinoma of Lung · Neuroendocrine Carcinoma of Thymus·Matched via name phrase
- NCT07328074·NOT YET RECRUITING·Electrocautery Resection Combined With HITHOC for Thymic Epithelial Tumors With Pleural Metastasis
Conditions: Thymic Epithelial Tumor · Thymoma · Thymic Carcinoma · Pleural Metastasis·Matched via name phrase
- NCT01385722·ENROLLING BY INVITATION·Molecular Analysis of Thoracic Malignancies
Conditions: Thymus Cancer · Thymoma · Thymic Carcinoma · Lung Cancer·Matched via name phrase
- NCT05667948·RECRUITING·Molecular Analysis and Treatment Options of Thymic Malignancies
Conditions: Thymic Epithelial Tumor · Thymic Carcinoma · Thymic Cancer·Matched via name phrase
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Thymic carcinoma" OR "carcinoma of thymus" OR "carcinoma of the thymus" OR "malignant thymoma" OR "thymic carcinoma (excluding well differentiated thymic carcinoma)" OR "thymic carcinoma excluding well differentiated thymic carcinoma" OR "thymoma type C" OR "thymoma, malignant" OR "thymoma, malignant (morphologic abnormality)" OR "thymoma, type C (morphologic abnormality)" OR "thymus carcinoma" OR "type C thymoma"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Thymic carcinoma" OR "carcinoma of thymus" OR "carcinoma of the thymus" OR "malignant thymoma" OR "thymic carcinoma (excluding well differentiated thymic carcinoma)" OR "thymic carcinoma excluding well differentiated thymic carcinoma" OR "thymoma type C" OR "thymoma, malignant" OR "thymoma, malignant (morphologic abnormality)" OR "thymoma, type C (morphologic abnormality)" OR "thymus carcinoma" OR "type C thymoma"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 63 interventional · 7 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
- Publication count (7232) is extremely high with unknown/missing prevalence — treat as possible over-matching, not proven research intensity
Ingested 2026-07-27T06:26:33.413Z
